Advanced Glycation End Products (AGEs):
- David S. Klein, MD FACA FACPM

- Jan 16
- 4 min read
A Silent Driver of Atherosclerotic Cardiovascular Disease
Introduction
If you are truly interested in a healthy diet, if you are truly interested in learning the why and how of nutrition and nutritional medicine, this is article is an important investment of your valuable time. While it seems like a very dry, academic topic, it is likely to change your behavior in a meaningful and healthy way. Please share this one with your friends and family, it may change them, for the better, as well.
Background
Atherosclerotic cardiovascular disease (ASCVD) is often framed as a problem of cholesterol alone. While lipoproteins remain central, this view is incomplete. A growing body of evidence points to advanced glycation end products (AGEs) as a powerful, under-recognized contributor to vascular aging, endothelial dysfunction, inflammation, and plaque instability.
AGEs accumulate slowly and quietly over decades. By the time ASCVD becomes clinically evident, the biological damage has often been underway for years. Understanding AGEs changes how we think about cardiovascular risk, prevention, and longevity.
What Are Advanced Glycation End Products?

AGEs are harmful compounds formed when sugars react non-enzymatically with proteins, lipids, or nucleic acids, a process known as the Maillard reaction. This reaction accelerates under conditions common in modern life:
Chronic hyperglycemia
Insulin resistance and diabetes
Oxidative stress
High-temperature food preparation (grilling, frying, roasting)
Once formed, AGEs are biologically persistent. They accumulate in long-lived tissues such as vascular collagen, myocardium, kidney, retina, and neural tissue¹².
Endogenous vs Exogenous AGEs
Endogenous AGEs
Produced within the body as a consequence of:
Elevated glucose exposure
Mitochondrial oxidative stress
Aging-related metabolic inefficiency
Exogenous AGEs
Absorbed directly from food, particularly:
Charred meats
Fried foods
Baked and roasted products
Ultra-processed foods
Dietary AGEs significantly raise circulating AGE burden and inflammatory markers, independent of calories or macronutrient composition³⁴.

AGEs contribute to atherosclerosis through multiple converging mechanisms:
1. Endothelial Dysfunction
AGEs cross-link collagen within the arterial wall, increasing stiffness and impairing nitric oxide signaling. The result is reduced vasodilation and increased shear stress⁵⁶.
2. Chronic Inflammation via RAGE

AGEs bind to the Receptor for Advanced Glycation End Products (RAGE), activating NF-κB and sustaining low-grade vascular inflammation. This signaling loop perpetuates oxidative stress and cytokine production⁷⁸.
3. LDL Modification and Foam Cell Formation
Glycated LDL is more readily oxidized and less efficiently cleared, promoting macrophage uptake and foam cell formation, a hallmark of early plaque development⁹.
4. Plaque Instability
AGE accumulation weakens fibrous caps and promotes metalloproteinase activity, increasing the risk of plaque rupture and thrombosis¹⁰.
AGEs, Diabetes, and “Residual Risk”
Even in well-controlled diabetes, AGEs persist due to prior glycemic exposure, a phenomenon known as metabolic memory¹¹. This explains why cardiovascular risk often remains elevated despite improved A1c levels.
Importantly, AGE burden also rises in non-diabetic individuals with insulin resistance, visceral adiposity, and sedentary lifestyles, making this a broader cardiometabolic issue¹².
Clinical Markers and Assessment
While AGEs are not yet part of routine cardiovascular screening, several surrogate indicators raise suspicion for elevated AGE burden:
Elevated fasting insulin
Increased HbA1c within “normal” range
Oxidative stress markers
Vascular stiffness (pulse wave velocity)
Skin autofluorescence (research and select clinical settings)¹³
Reducing AGE Burden: Practical Strategies
Nutrition
Favor steaming, boiling, poaching over grilling or frying
Emphasize whole, unprocessed foods
Reduce refined carbohydrates and fructose exposure
Glycemic Control
Optimize insulin sensitivity
Address post-prandial glucose excursions
Antioxidant and Nutrient Support
N-acetylcysteine (NAC)
Alpha-lipoic acid
Vitamin C and E
Polyphenols (curcumin, resveratrol)¹⁴
Lifestyle
Regular aerobic and resistance exercise
Weight optimization
Sleep and stress regulation
What you can do, right now:

Control your sugar intake: Limit refined sugars, soft drinks, alcohol
Modify cooking: Boil and steaming food is healthier than baking, frying and grilling (particularly over open flame)
Eat whole (unprocessed) foods: A good start is the Mediterranean diet.
These interventions reduce AGE formation, enhance clearance, and blunt RAGE-mediated inflammation¹⁵.
Why This Matters Clinically
AGEs provide a unifying mechanism linking aging, diabetes, oxidative stress, and ASCVD. Addressing them shifts cardiovascular care from reaction to prevention and reframes risk assessment beyond cholesterol alone.
For patients focused on longevity, vascular health, and cognitive preservation, AGE reduction represents a meaningful and actionable target.
REFERENCES
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820.https://pubmed.ncbi.nlm.nih.gov/11742414/
Singh R, et al. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–146.https://pubmed.ncbi.nlm.nih.gov/11270668/
Uribarri J, et al. Dietary advanced glycation end products and their role in health and disease. Adv Nutr. 2015;6(4):461–473.https://pubmed.ncbi.nlm.nih.gov/26178075/
Vlassara H, et al. Dietary glycotoxins. Proc Natl Acad Sci U S A. 2002;99(24):15596–15601.https://pubmed.ncbi.nlm.nih.gov/12429856/
Semba RD, et al. Advanced glycation end products and arterial stiffness. J Gerontol A Biol Sci Med Sci. 2009;64A(7):742–748.https://pubmed.ncbi.nlm.nih.gov/19359445/
Goldin A, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605.https://pubmed.ncbi.nlm.nih.gov/16894049/
Ramasamy R, et al. Receptor for advanced glycation end products and inflammation. J Clin Invest. 2009;119(10):2523–2532.https://pubmed.ncbi.nlm.nih.gov/19729818/
Schmidt AM, et al. RAGE signaling in vascular disease. Arterioscler Thromb Vasc Biol. 2010;30(8):1509–1517.https://pubmed.ncbi.nlm.nih.gov/20595672/
Bucala R, et al. Modification of LDL by advanced glycation end products. Proc Natl Acad Sci U S A. 1994;91(20):9441–9445.https://pubmed.ncbi.nlm.nih.gov/7937785/
Basta G, et al. Advanced glycation end products activate endothelial cells. Cardiovasc Res. 2004;63(2):267–275.https://pubmed.ncbi.nlm.nih.gov/15249186/
Ceriello A. The concept of metabolic memory. Diabetes Care. 2009;32(Suppl 2):S245–S250.https://pubmed.ncbi.nlm.nih.gov/19875544/
Baynes JW. Role of oxidative stress in development of complications in diabetes. Free Radic Biol Med. 2001;31(9):1157–1170.https://pubmed.ncbi.nlm.nih.gov/11677047/
Meerwaldt R, et al. Skin autofluorescence as a measure of AGE accumulation. Diabetes Care. 2004;27(10):2246–2251.https://pubmed.ncbi.nlm.nih.gov/15451899/
Ziegler D, et al. Alpha-lipoic acid in the treatment of diabetic neuropathy. Diabetes Care. 1999;22(8):1296–1301.https://pubmed.ncbi.nlm.nih.gov/10480775/
Uribarri J, et al. Restriction of dietary advanced glycation end products improves insulin resistance. Diabetes Care. 2011;34(7):1610–1616.https://pubmed.ncbi.nlm.nih.gov/21617107/
The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances.
1917 Boothe Circle, Suite 171
Longwood, Florida 32750
Tel: 407-679-3337
Fax: 407-678-7246











.webp)